Impressum Bookmark Kontakt Sitemap
Hämoblastosen - Myelodysplastische Syndrome - Weiterführende Informationen

Myelodysplastische Syndrome

Leitlinien

 

www.dgho-onkopedia.de → Leitlinien (KD Hofmann, 02/2011)

 

Studien

 

www.kompetenznetz-leukaemie.de, www.studien.de, www.eortc.be, www.clinicaltrials.gov

 

Literatur

 

  1. Lyons RM: Hematologic response to three alternative dosing schedules of azacitidine in patients with MDS; JCO 2009; 27: 1850–6
  2. Fenaux P et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–32
  3. Cazzola M, Malcovati L: Risk-adapted treatment of myelodysplastic Syndromes. Hematology Education of the EHA 2009; 181–7
  4. Clavio M et al: Haematopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy? J Exp Clin Cancer Res 2005; 24: 5–16
  5. Fenaux P, Gardin C: Epigenetic therapy in MDS. Hematology Education of the EHA 2007; 1: 205–14
  6. EHA Hematology Education 2011
  7. Kantarjian H, Issa JP: Decitabine improves patient outcomes in myelodysplastic syndromes: result of a phase III randomised study. Cancer 2006; 106: 1794–803
  8. Silverman LR et al: Further analysis of trials with azacitidine in patients with MDS: studies 8421, 8921 and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895–903